Home › Funds › Balyasny Asset Management › STRO
Balyasny Asset Management position in STRO
SUTRO BIOPHARMA INC · Health Care
Latest position (Q2 2026)711.16K sh
Reported value held$23.61M
Portfolio Weight0.03%
First reportedQ4 2022
Last changeAdd
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2022 | 17.61K | $142.29K | New |
| Q2 2023 | 214.02K | $995.20K | New |
| Q4 2025 | 230.05K | $2.66M | New |
| Q1 2026 | 465.79K | $11.60M | Add |
| Q2 2026 | 711.16K | $23.61M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding STRO
- BlackRock Inc 1.12M sh · $37.27M · Q2 2026
- Geode Capital Management 389.69K sh · $12.94M · Q2 2026
- Millennium Management 365.97K sh · $12.15M · Q2 2026
- Point72 Asset Management 237.83K sh · $7.90M · Q2 2026
- UBS Group AG 208.51K sh · $6.92M · Q2 2026
- Two Sigma Investments 201.69K sh · $6.70M · Q2 2026
- Marshall Wace 175.25K sh · $5.82M · Q2 2026
- JPMorgan Chase & Co 159.63K sh · $5.32M · Q2 2026
- Goldman Sachs Group 149.22K sh · $4.95M · Q2 2026
- Vanguard Group 375.79K sh · $4.35M · Q4 2025
- Northern Trust Corp 125.93K sh · $4.18M · Q2 2026